

► FTSE Investor Update

Wednesday 17th August 2022

Qinetiq wins US contract and announces US acquisition

It's been a good couple of weeks for **Qinetiq's (QQ.)** US growth prospects...

Earlier this month, Qinetiq announced that it has entered into an agreement to acquire Avantus Federal LLC from NewSpring Holdings, for an enterprise value of \$590m (£483m).

Avantus is a leading provider of mission-focused cyber, data analytics and software development solutions to the US Department of Defense, Intelligence Community, Department of Homeland Security and other Federal civilian agencies.

In the 12 months to 30 June 2022, Avantus generated revenues of \$298m, adjusted earnings (EBITDA) of \$35.5m and adjusted operating profit of \$32m. The deal will generate a tax benefit for Qinetiq of approximately \$70m.

The US acquisition has been followed by a US contract win...

Qinetiq announced last week that it had won a contract to provide technical services to the US Army.

The five-year contract, worth up to \$45m, will provide services for the Development Command (DEVCOM) Command, Control, Computers, Communications, Cyber, Intelligence, Surveillance and Reconnaissance (C4ISR) at the Fort Belvoir Prototyping Integration Facility (PIF).



QQ. Daily Candle Chart



AstraZeneca says data confirms Enhertu benefit in breast cancer patients

Enhertu, **AstratZeneca (AZN)** and Daiichi Sankyo's breast cancer drug continues to gather positive momentum...


On Monday, AstraZeneca said a late-stage trial had confirmed the benefit of Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.

In a 600-patient trial called DESTINY-Breast02, Enhertu was compared against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer.

The study showed that Enhertu met the main goal of statistically significant and clinically meaningful improvement in progression-free survival, a measure of how long a person can live without their disease worsening. The drug also improved overall survival, a key secondary goal.

This positive study news comes on the back of Enhertu securing faster-than-expected US approval, in patients with a particular form of breast cancer.

The new US Food and Drug Administration (FDA) approval – for patients with 'HER2-low' breast cancer – has opened a large, new multibillion-dollar market for AstratZeneca and Daiichi Sankyo.



► Performance

FTSE Investor Update - Wednesday 17th August 2022

The table below shows performance data for every FTSE Investor open position since the service was launched in April 2022*

Name	Ticker	Growth	Value	Income	Open Date	Entry Price	Current Price*	Total Return**
Qinetiq	QQ.		✓		06/04/2022	316	364.8	16.44%
Unilever	ULVR		✓	✓	20/04/2022	3,431.20	3919	14.21%
Centrica	CNA		✓		04/05/2022	79.34	83.42	5.14%
Vodafone	VOD			✓	18/05/2022	114.12	123.08	10.85%
Moneysupermarket.com	MONY		✓	✓	01/06/2022	183.11	214.6	17.19%
AstraZeneca	AZN	✓	✓		15/06/2022	9,821	10918	11.16%
ME Group	MEGP	✓			29/06/2022	76.40	104.9	37.30%
Ashtead	AHT	✓			13/07/2022	3,743	4622	23.48%
Auto Trader	AUTO	✓			27/07/2022	594.3	654.4	10.11%
JD Sports	JD.	✓	✓		10/08/2022	127.6	129.55	1.52%

DISCLAIMER - All content is provided for general information only and should not be construed as any form of advice or personal recommendation. The provision of this content is not regulated by the Financial Conduct Authority.



*Prices correct as of 16th August 2022. **Total Return includes price movement and any dividends accrued during holding period. The table above shows ALL stock recommendations since FTSE Investor's launch on 6th April 2022. Please be aware that all entry and current price levels are mid-prices. No allowance for dealing costs, fees or taxes has been made. Past performance is not a guarantee of future performance.

All content is provided for general information only and should not be construed as any form of advice or personal recommendation. It does not take into consideration your personal circumstances, including your investment objectives, risk profile, tax status, knowledge and understanding or financial situation. Please ensure you fully understand the risks involved and seek independent advice if necessary.

Regency Research provides research for UK listed shares which can carry risk to your capital. The value of shares can fall as well as rise, which could mean getting back less than you originally invested. No liability is accepted for any loss or detriment in any way related to the content provided by Regency Research, the provision of which is not regulated by the Financial Conduct Authority.

Regency Research is a trading name of Regency Capital Group Ltd, registered in England and Wales (company number 11921999). Registered address at 35 Berkeley Square, Mayfair, London, United Kingdom, W1J 5BF. Regency Capital Group Ltd is authorised and regulated by the Financial Conduct Authority (FRN 916337). All prices quoted include VAT, charged at 20% (VAT number 397557923).